Dark

Check out our Level2View

RUBY
RUBIUS THERAPEUTICS INC
stock OTC

Inactive

Dec 29, 2023

0.0570USD+2.703%(+0.0015)755,858

Pre-market

0.00USD-100.000%(-0.06)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 17, 2022

09:05AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Jan 13, 2022

11:46AM EST Rubius Therapeutics Announces Dosing Of First Patient In Phase 1/2 Trial Of RTX-224, A Broad Immune Agonist, For Treatment Of Certain Solid Tumors Benzinga

08:00AM EST Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 GlobeNewswire Inc

Jan 10, 2022

08:00AM EST Continuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Expected in Q122 GlobeNewswire Inc

Jan 4, 2022

04:15PM EST Rubius Therapeutics to Present at the Virtual 40th Annual J.P. GlobeNewswire Inc

Dec 31, 2021

08:05AM EST RBC Global Asset Management Inc. announces final annual reinvested capital PR Newswire

Dec 22, 2021

09:05AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Dec 16, 2021

08:15AM EST Rubius Therapeutics Says To Highlight Programs At Platform And Pipeline Day In Q1 2022 Benzinga

08:00AM EST Highly Versatile and Programmable RED PLATFORM Enables Multiple Modalities to Target Different Immune Pathways Across a Range of Diseases GlobeNewswire Inc

Dec 2, 2021

09:00AM EST Rubius Therapeutics Named to the List of Top Places to Work in GlobeNewswire Inc

Dec 1, 2021

04:15PM EST Rubius Therapeutics to Host Virtual Preclinical Pipeline and GlobeNewswire Inc

Nov 24, 2021

04:05PM EST RBC Global Asset Management Inc. announces estimated annual reinvested capital PR Newswire

Nov 23, 2021

08:00AM EST Rubius Therapeutics to Participate in Evercore ISI 4th Annual GlobeNewswire Inc

Nov 16, 2021

09:06AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:00AM EST Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad GlobeNewswire Inc

Nov 9, 2021

11:24AM EST SVB Leerink Maintains Market Perform on Rubius Therapeutics, Lowers Price Target to $14 Benzinga

11:11AM EST Rubius Therapeutics Q3 EPS $(0.55) Beats $(0.57) Estimate Benzinga

08:30AM EST Rubius Therapeutics to Participate in Jefferies London Healthcare GlobeNewswire Inc

Nov 8, 2021

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Oct 28, 2021

09:00AM EDT Rubius Therapeutics, Inc.(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results onMonday, November 8, 2021, after market close. GlobeNewswire Inc

Oct 15, 2021

09:00AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Oct 13, 2021

10:12AM EDT Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize PR Newswire

Oct 1, 2021

08:03AM EDT Rubius Therapeutics Reports Preclinical Data For RTX-224 Will Be Presented At Society For Immunotherapy Of Cancer Meeting Nov. 12 At 7 a.m. EST Benzinga

08:00AM EDT Rubius Therapeutics Announces Preclinical Data for RTX-224, a GlobeNewswire Inc

Sep 23, 2021

09:00AM EDT /C O R R E C T I O N from Source -- RBC Global Asset Management Inc./ PR Newswire

Sep 16, 2021

09:33AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Sep 1, 2021

09:00AM EDT Rubius Therapeutics to Participate in the Morgan Stanley 19th GlobeNewswire Inc

Aug 30, 2021

08:13AM EDT Rubius Therapeutics Appoints Jim Jogerst As Chief Business Officer RTTNews

Aug 17, 2021

09:05AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

08:16AM EDT Rubius Therapeutics Q2 EPS $(0.56) Misses $(0.49) Estimate Benzinga

08:00AM EDT First Patient Dosed with RTX-240 in Combination with KEYTRUDA (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Patients with Advanced Solid Tumors GlobeNewswire Inc

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 29, 2021

08:15AM EDT Rubius Therapeutics Appoints Dannielle Appelhans As Chief Operating Officer Benzinga

08:00AM EDT Rubius Therapeutics Appoints Dannielle Appelhans as Chief GlobeNewswire Inc

Jul 22, 2021

08:30AM EDT Rubius Therapeutics, Inc.(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results onMonday, August 9, 2021, before market open. GlobeNewswire Inc

Jul 16, 2021

09:01AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for July PR Newswire

Jul 15, 2021

08:10AM EDT Rubius Therapeutics Announces Publication Of RTX-240 Preclincal Data In Cancer Immunology, Immunotherapy Benzinga

08:00AM EDT Rubius Therapeutics Announces Publication of RTX-240 Preclinical GlobeNewswire Inc

Jun 23, 2021

04:01PM EDT Rubius Therapeutics Reports First Patient Dosed In RTX-240 In Combo With KEYTRUDA In Ongoing Phase 1/2 Trial For Treatment Of Advanced Solid Tumors Benzinga

04:01PM EDT Rubius Therapeutics Announces First Patient Dosed with RTX-240 in GlobeNewswire Inc

Jun 22, 2021

10:18AM EDT /C O R R E C T I O N from Source -- RBC Global Asset Management Inc./ PR Newswire

Jun 16, 2021

08:33AM EDT RBC Global Asset Management Announces RBC ETF Cash Distributions For June RTTNews

08:30AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for June PR Newswire

Jun 14, 2021

07:52PM EDT at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative PR Newswire

May 25, 2021

06:01AM EDT Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological PR Newswire

May 20, 2021

08:30AM EDT Rubius Therapeutics to Participate in Jefferies Virtual Healthcare GlobeNewswire Inc

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:02PM EDT Rubius Therapeutics to Present Trials in Progress Poster on the GlobeNewswire Inc

09:46AM EDT Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening RTTNews

09:04AM EDT Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat PR Newswire

May 18, 2021

10:28AM EDT Morgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Raises Price Target to $25 Benzinga

May 12, 2021

09:01AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for May PR Newswire

08:06AM EDT Rubius Therapeutics Highlights Publication Of RTX-321 Preclinical Data In Nature Communications Benzinga

08:00AM EDT Rubius Therapeutics Announces Publication of RTX-321 Preclinical GlobeNewswire Inc

May 10, 2021

08:08AM EDT Rubius Therapeutics Q1 EPS $(0.51) Beats $(0.52) Estimate Benzinga

08:00AM EDT Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM;Dose Optimization and Enrollment Continues GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

Apr 26, 2021

08:00AM EDT Rubius Therapeutics, Inc.(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results onMonday, May 10, 2021, before market open. GlobeNewswire Inc

Apr 19, 2021

11:09AM EDT Morgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Raises Price Target to $24 Benzinga

Apr 16, 2021

09:00AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for April PR Newswire

Apr 12, 2021

08:03AM EDT Rubius Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Of RTX-321 For Treatment Of HPV 16-Positive Cancers Benzinga

08:00AM EDT Rubius Therapeutics Announces First Patient Dosed in Phase 1 GlobeNewswire Inc

Apr 9, 2021

08:02AM EDT Rubius Therapeutics Presents Initial Clinical Results From Ongoing Phase 1/2 Clinical Trial Of RTX-240 In Advanced Solid Tumors At American Association Of Cancer Research Virtual Annual Meeting Benzinga

08:00AM EDT Rubius Therapeutics Presents Initial Clinical Results from the GlobeNewswire Inc

Mar 30, 2021

09:30AM EDT Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion PR Newswire

Mar 28, 2021

08:15AM EDT The Past Week's Notable Insider Buys: Babcock & Wilcox, Designer Brands And More Benzinga

Mar 17, 2021

12:26PM EDT Mid-Day Market Update: Dow Gains 100 Points; Rubius Therapeutics Shares Plummet Benzinga

09:00AM EDT RBC Global Asset Management Inc. Announces RBC ETF Cash Distributions for March PR Newswire

05:36AM EDT Rubius Therapeutics Priced Upsized ~6.9M Share Public Offering of Common Stock @$29/Share Benzinga

Mar 16, 2021

09:29PM EDT Rubius Therapeutics Prices Upsized Public Offering of Common Stock GlobeNewswire Inc

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

04:33PM EDT Rubius Therapeutics Announces Proposed Offering Of $150M Of Common Stocks Benzinga

04:32PM EDT Rubius Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

02:51PM EDT Mid-Afternoon Market Update: Dow Rises 50 Points; Shaw Communications Shares Spike Higher Benzinga

02:06PM EDT Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study Benzinga

01:26PM EDT HC Wainwright Raised Price Target On Rubius Therapeutics From $28 To $40 Benzinga

01:00PM EDT SVB Leerink Maintains Market Perform on Rubius Therapeutics, Raises Price Target to $20 Benzinga

12:59PM EDT HC Wainwright & Co. Maintains Buy on Rubius Therapeutics, Raises Price Target to $40 Benzinga

12:04PM EDT Mid-Day Market Update: Intec Pharma Jumps Following Merger News; HighPoint Resources Shares Plunge Benzinga

10:25AM EDT Mid-Morning Market Update: Markets Edge Higher; Roche To Acquire GenMark Diagnostics In $1.8B Deal Benzinga

07:48AM EDT UPDATE: Rubius Therapeutics Reports Confirmed Partial Response With 54% Reduction In Target Lesions At 1e8 Dose Benzinga

07:42AM EDT UPDATE: Rubius Therapeutics Says Initial Clinical Data Provide Evidence Of Broad Potential Of RED PLATFORM Across Pipeline Of Cancer And Autoimmune Programs Benzinga

07:41AM EDT Rubius Therapeutics Reports Initial Clinical Data From Ongoing Phase 1/2 Trial Of RTX-240 In Patients With Advanced Solid Tumors; Says RTX-240 Generated Partial Responses In Metastatic Anal Cancer And Metastatic Uveal Melanoma Patients, Benzinga

07:39AM EDT RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events GlobeNewswire Inc

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 12, 2021

04:30PM EST Rubius Therapeutics Announces Webcast to Review Initial Clinical GlobeNewswire Inc

Mar 11, 2021

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Mar 10, 2021

04:33PM EST Rubius Therapeutics Highlights Will Present Trial Results From Ongoing Phase 1/2 Trial Of RTX-240 In Advanced Solid Tumors At American Association Of Cancer Research Meeting Apr. 10-15 Benzinga

04:30PM EST Rubius Therapeutics to Present Initial Clinical Results from the GlobeNewswire Inc

Feb 25, 2021

07:01AM EST Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire

Feb 23, 2021

10:29AM EST SVB Leerink Maintains Market Perform on Rubius Therapeutics, Lowers Price Target to $4 Benzinga

08:26AM EST Rubius Therapeutics Says Continues To Enroll Patients In Second Phase 1 Arm Of RTX-240 Clinical Trial; Says Expects To Dose First Patient In RTX-321 Clinical Trial Of HPV 16-Positive Tumors In 2021 Benzinga

08:22AM EST Rubius Therapeutics Q4 EPS $(0.50) Misses $(0.49) Estimate Benzinga

08:00AM EST Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 GlobeNewswire Inc

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 18, 2021

08:00AM EST Rubius Therapeutics to Participate in the 10th Annual SVB Leerink GlobeNewswire Inc

Feb 12, 2021

09:00AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Feb 9, 2021

08:00AM EST Rubius Therapeutics, Inc.(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood cells into medicines, called Red Cell Therapeutics, for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2020 financial results onTuesday, February 23, 2021, before market open. GlobeNewswire Inc

Feb 3, 2021

04:47PM EST Rubius Therapeutics to Participate in Guggenheim Healthcare Talks GlobeNewswire Inc

Jan 29, 2021

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 19, 2021

09:59AM EST Morgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Raises Price Target to $10 Benzinga

Jan 15, 2021

09:00AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Jan 11, 2021

08:00AM EST Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism Additional Results to be Presented in Early 2021 GlobeNewswire Inc

Jan 4, 2021

04:01PM EST Rubius Therapeutics to Present at the Virtual 39th Annual J.P. GlobeNewswire Inc

Dec 31, 2020

09:03AM EST RBC Global Asset : Unitholders To Receive 2020 Annual Reinvested Capital Gains Distribution Amounts RTTNews

09:00AM EST RBC Global Asset Management Inc. announces final annual reinvested capital PR Newswire

Dec 22, 2020

09:00AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

07:55AM EST RBC Global Asset Management Inc. announces estimated annual reinvested capital PR Newswire

Nov 30, 2020

04:00PM EST Rubius Therapeutics to Participate in Evercore ISI3rd GlobeNewswire Inc

Nov 26, 2020

05:00PM EST RBC Global Asset Management Inc. announces estimated annual reinvested capital PR Newswire

Nov 13, 2020

09:00AM EST RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Nov 11, 2020

08:20AM EST Morgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Raises Price Target to $5 Benzinga

Nov 10, 2020

04:01PM EST Rubius Therapeutics to Participate in Jefferies Virtual London GlobeNewswire Inc

Nov 9, 2020

08:35AM EST Rubius Therapeutics Presents Preclinical Data For Lead Red Cell Therapeutic Clinical Oncology Program, RTX-240, At The Society For Immunotherapy Of Cancer's Annual Meeting Benzinga

08:10AM EST Rubius Therapeutics Q3 EPS $(0.51) Misses $(0.49) Estimate Benzinga

08:05AM EST Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2Solid Tumor Clinical Trial GlobeNewswire Inc

08:00AM EST Rubius Therapeutics Presents Preclinical Data for Lead Red Cell GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

08:00AM EST Rubius Therapeutics Announces Dosing of First Patient with GlobeNewswire Inc

07:59AM EST Rubius Therapeutics Reports Dosing Of First Patient With Relapsed/Refractory Acute Myeloid Leukemia In Ongoing Phase 1/2 Trial Of RTX-240 Benzinga

Oct 28, 2020

05:17AM EDT Rubius Therapeutics Presented Preclinical Data for RTX-321, a Red Cell Therapeutic Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action Benzinga

05:00AM EDT Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red GlobeNewswire Inc

Oct 16, 2020

09:00AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Oct 15, 2020

08:09AM EDT Rubius Therapeutics Announces Preclinical Data Supporting Its Lead Clinical Oncology Program, RTX-240, To Be Presented At The Society For Immunotherapy Of Cancer's Annual Meeting Benzinga

08:00AM EDT Rubius Therapeutics Announces Preclinical Data Supporting its Lead GlobeNewswire Inc

Sep 29, 2020

04:01PM EDT Rubius Therapeutics, Inc.(Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Laurence Turka, M.D., chief scientific officer, will participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 4:00 p.m. ET. GlobeNewswire Inc

Sep 28, 2020

08:14AM EDT Rubius Therapeutics Appoints Jose Carmona As CFO RTTNews

08:05AM EDT Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer Benzinga

Sep 16, 2020

09:01AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Sep 8, 2020

04:01PM EDT Rubius Therapeutics, Inc.(Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it will participate in the following investor conferences: GlobeNewswire Inc

Aug 17, 2020

09:00AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for PR Newswire

Aug 10, 2020

08:29AM EDT Rubius Therapeutics Q2 EPS $(0.47) Beats $(0.50) Estimate Benzinga

08:00AM EDT Strong Momentum in Dosing Patients and Manufacturing Clinical Supply forRTX-240 Phase 1/2 Solid Tumor Clinical Trial GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

04:01PM EDT Rubius Therapeutics, Inc.(Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report second quarter 2020 financial results onMonday, August 10, 2020, before market open. GlobeNewswire Inc

Jul 17, 2020

09:00AM EDT RBC Global Asset Management Inc. announces RBC ETF cash distributions for July PR Newswire

Share